The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Novo Nordisk will pay as much as $2 billion for a new obesity drug called UBT251 The company now holds the exclusive rights to develop, manufacture and sell the drug in much of the world It has ...

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...

Novo Nordisk (NYSE: NVO) just struck a big deal with a Chinese drugmaker, The United Laboratories International Holdings Limited, to license a new weight-loss and diabetes drug, UBT251 (4).